The Importance of Skin Preparation

Total Page:16

File Type:pdf, Size:1020Kb

The Importance of Skin Preparation AESTHETIC FOCUS The importance of skin preparation BY ANNA BAKER With both aesthetic procedures and antibiotic resistance on the rise, good skin disinfection to reduce the risk of infection is more vital than ever. Anna Baker takes us through the evidence behind commonly used skin preparation formulations for aesthetic injectable treatments. he global number of aesthetic the skin [7]. This paper will explore some described as insusceptible, phenotypically procedures performed continues of the commonly used skin preparation tolerant, tolerant or resistant to antiseptics to rise exponentially [1]. The recent formulations used for aesthetic injectable [17]. Consistent with antibiotics, resistance Tdata from The American Society for treatments. to antiseptics can be intrinsic or acquired. Aesthetic Plastic Surgery (2017) confirms Intrinsic resistance, or insusceptibility, to an overall 5.1% increase in the number Chlorhexidine chlorhexidine is demonstrated by bacterial of aesthetic procedures undertaken, Chlorhexidine is a divalent, cationic spores and mycobacteria [17]. In both in comparison to those performed biguanide antiseptic agent that that was cases the outer layers of the cell form an in 2016; as well as a 40.6% increase first described in 1954 [8]. Chlorhexidine impermeable barrier to the ingress of the over the past five years. Furthermore, exists as a gluconate, acetate and molecules [11]. There are inconsistences in non-surgical procedures increased by hydrochloride salts [9]. It has a wide the literature when attempting to define 4.2% in 2017, compared to 2016. As a spectrum of activity encompassing gram- a consensus definition of ‘chlorhexidine consequence, a growing incidence of positive and gram-negative bacteria, resistance,’ as well as in defining a associated complications are described yeasts, dermatophytes, fungi and some robust and standardised method for the [2]. Furthermore, data from the US Food lipophilic viruses [7,10] but is ineffective detection of reduced susceptibility and / and Drug Administration (FDA) in 2017, against bacterial spores [11]. Chlorhexidine or resistance to in-use concentrations of indicates a three-fold rise in adverse at low concentrations is bacteriostatic, chlorhexidine [17]. These are challenging reactions from 2008 to 2011, compared whereas at higher concentrations it can concepts to quantify owing to the gaps and with 2005 to 2007 [3]. be rapidly bactericidal [8]. Chlorhexidine inconsistencies in the literature with scope Alhede et al. reported on a murine acts by binding to the negatively charged for further research. study showing that pseudomonas, bacterial cell wall and affecting the osmotic In contrast, the Medicines and staphylococcus, and propionibacterium equilibrium of the cell [12]. Chlorhexidine Healthcare products Regulatory Agency were all cultured following administration effectively reduces numbers of bacterial (MHRA) issued a warning in 2012 for the of hyaluronic acid, polyacrylamide gel, poly- skin flora, and is available for use in use of chlorhexidine in light of a risk of L-lactic acid and calcium hydroxyapatite aqueous form, combined 70% alcohol and anaphylactic reaction due to chlorhexidine microspheres into the dermal pocket has been used in preparations for hand allergy [18]. A subsequent warning [4]. Furthermore, their findings also cleansing, both general and pre-surgical, for was published in 2017 by the US FDA demonstrated that once biofilm was more than 50 years [13]. reiterating a similar concern, reporting established, treatment with high dose Alongside a broad range of activity, 52 cases of worldwide anaphylaxis due to antibiotics was unable to eradicate the a key advantage of chlorhexidine when chlorhexidine gluconate [19]. In addition, infection. Antibiotic resistance is one of the used as a skin disinfectant, was its in the 46 years between January 1969 most significant threats to patient safety ‘residual activity’ [14]. Furthermore, Aly and June 2015, the FDA reports 43 cases in Europe, fuelled by overuse of antibiotics and Maibach propose that in comparison worldwide. These statistics reinforce and inappropriate prescribing [5]. These to povidone iodine, chlorhexidine can the need for a comprehensive medical cumulative factors emphasise a growing produce a greater reduction in the skin consultation, which includes details need and awareness of utilising adequate flora, as well as exerting a longer residual regarding known sensitivities and allergies. precautions to reduce the risk of associated activity [14], although, irritation of the skin complications, and attention to appropriate and allergic reactions such as dermatitis, Isopropyl alcohol skin disinfection during all stages of a non- are more commonly reported at higher Alcohols are classified into primary, surgical procedure is key [6]. concentrations [15]. secondary and tertiary alcohols, on the Chan et al. propose that the desirable Historically, chlorhexidine has been one basis of the number of carbon atoms traits of a good skin decontaminant of the most frequently used antiseptic linked to the carbon atom that bears the are that it can effectively remove the agents, yet, there are a small number of hydroxyl group [20]. Isopropyl alcohol, contaminant of interest, is readily reports within the literature of bacterial or isopropanolol, is a secondary alcohol, available, acts rapidly, does not enhance resistance to biocides, antibiotic resistance a structured isomer of propranolol, that percutaneous penetration / absorption of effects of biocides, as well as potential for can be produced by combining water and the contaminant, can be readily removed reduced susceptibility to chlorhexidine propene [21]. It is a clear and flammable without residue, and does not damage in staphylocci [16,17]. Bacteria may be liquid that has a moderate evaporation The PMFA Journal | JUNE/JULY 2018 | VOL 5 NO 5 | www.thepmfajournal.com AESTHETIC FOCUS rate and is widely used as an industrial in addition to cytosolic enzymes involved hypochlorous acid [35]. Furthermore, solvent, and cleaning fluid, and is present in the respiratory chain, causing them Robson et al. concur that stabilised in many products, such as lacquers, inks, to become denatured and deactivated hypochlorous acid has rapid and broad- and thinners, as well as household products [25]. In addition, the combination of spectrum antimicrobial activity against [20]. In the EU, it is approved for use in alcohol and iodine has demonstrated clinically relevant microorganisms in vitro cosmetics as a solvent, an antifoaming good effectiveness, in comparison to and in vivo, as long as the narrow effective agent, a perfuming agent, and a viscosity alcohol alone, which may be a result of the pH range is maintained [36]. controller. In light of its antimicrobial immediate germicidal action of alcohol and In vivo, hypochlorous acid is produced activity (which includes multidrug-resistant the residual activity of iodine [30]. Data on in the intracellular matrix in response pathogens, mycobacterium tuberculosis, the systemic absorption of antiseptics is to phagocytosis of pathogens by and a variety of fungi), isopropyl alcohol limited and iodine seems to be absorbed neutrophils and plays an important is accepted as a preservative, and as an from the skin, but more significantly role in the destruction of pathogens. antiseptic in the clinical environment [22.] from mucosa [25], although, this may be The hypochlorous technology has been Alcohol is fast and short acting, with determined by the condition of the skin developed further by Clinical Health broad-spectrum antimicrobial activity, and barrier at the site of application [31]. Technologies to formulate a solution is relatively inexpensive [23]. It is believed Iodine based formulations are highly which has a skin neutral pH which the that alcohols cause membrane damage effective for surgical procedures owing to manufacturer claims to deliver a 6 log and rapid denaturation of proteins, with their broad antimicrobial properties, yet reduction within seconds, with a highly subsequent interference with metabolism the residual, and temporary discolouration oxidising action which is not subject to and cell lysis [11]. Alcohol-based solutions of skin following application may be antimicrobial resistance. Clinisept+ is a that contain chlorhexidine gluconate challenging in terms of practicality for stable, non-toxic, non-mutagenic, and or iodophores are reported to exert a practitioners administering aesthetic non-irritant to skin, eyes and mucosa with sustained and durable antimicrobial injectable treatments. non-cytotoxic properties to new skin cells activity that can persist after alcohol and is designed for topical use, pre and post evaporation [11]. In addition, alcohol-based Chlorine based and Hypochlorous treatment. Hypochlorous has been well solutions can cause irritation if applied solutions described to possess anti-bacterial, anti- to mucous membranes [23]. Isopropyl Sodium hypochlorite was the first sporicidal, anti-fungal and anti-virucidal alcohol remains a popular choice for antiseptic used to prevent infection, as properties [35] and is well positioned as skin preparation for aesthetic injectable demonstrated in the 19th century by the a current, strong contender to meet the treatments, yet, there are reports within pioneering work of Ignaz Semmelweis, demands of a safe, versatile and effective the literature of skin sensitivity and who used it to disinfect hands, lowering skin preparation
Recommended publications
  • Utilization of Lactic Acid in Human Myotubes and Interplay with Glucose and Fatty Acid Metabolism Received: 12 January 2018 Jenny Lund1, Vigdis Aas2, Ragna H
    www.nature.com/scientificreports OPEN Utilization of lactic acid in human myotubes and interplay with glucose and fatty acid metabolism Received: 12 January 2018 Jenny Lund1, Vigdis Aas2, Ragna H. Tingstad2, Alfons Van Hees2 & Nataša Nikolić1 Accepted: 11 June 2018 Once assumed only to be a waste product of anaerobe glycolytic activity, lactate is now recognized as Published: xx xx xxxx an energy source in skeletal muscles. While lactate metabolism has been extensively studied in vivo, underlying cellular processes are poorly described. This study aimed to examine lactate metabolism in cultured human myotubes and to investigate efects of lactate exposure on metabolism of oleic acid and glucose. Lactic acid, fatty acid and glucose metabolism were studied in myotubes using [14C(U)] lactic acid, [14C]oleic acid and [14C(U)]glucose, respectively. Myotubes expressed both the MCT1, MCT2, MCT3 and MCT4 lactate transporters, and lactic acid was found to be a substrate for both glycogen synthesis and lipid storage. Pyruvate and palmitic acid inhibited lactic acid oxidation, whilst glucose and α-cyano-4-hydroxycinnamic acid inhibited lactic acid uptake. Acute addition of lactic acid inhibited glucose and oleic acid oxidation, whereas oleic acid uptake was increased. Pretreatment with lactic acid for 24 h did not afect glucose or oleic acid metabolism. By replacing glucose with lactic acid during the whole culturing period, glucose uptake and oxidation were increased by 2.8-fold and 3-fold, respectively, and oleic acid oxidation was increased 1.4-fold. Thus, lactic acid has an important role in energy metabolism of human myotubes. Lactate is produced from glucose through glycolysis and the conversion of pyruvate by lactate dehydrogenase (LDH).
    [Show full text]
  • Lactate Like Fluconazole Reduces Ergosterol Content in the Plasma Membrane and Synergistically Kills Candida Albicans
    International Journal of Molecular Sciences Article Lactate Like Fluconazole Reduces Ergosterol Content in the Plasma Membrane and Synergistically Kills Candida albicans Jakub Suchodolski 1, Jakub Muraszko 1 , Przemysław Bernat 2 and Anna Krasowska 1,* 1 Department of Biotransformation, Faculty of Biotechnology, University of Wrocław, 50-383 Wrocław, Poland; [email protected] (J.S.); [email protected] (J.M.) 2 Department of Industrial Microbiology and Biotechnology, Faculty of Biology and Environmental Protection, University of Łód´z,90-237 Łód´z,Poland; [email protected] * Correspondence: [email protected] Abstract: Candida albicans is an opportunistic pathogen that induces vulvovaginal candidiasis (VVC), among other diseases. In the vaginal environment, the source of carbon for C. albicans can be either lactic acid or its dissociated form, lactate. It has been shown that lactate, similar to the popular antifungal drug fluconazole (FLC), reduces the expression of the ERG11 gene and hence the amount of ergosterol in the plasma membrane. The Cdr1 transporter that effluxes xenobiotics from C. albicans cells, including FLC, is delocalized from the plasma membrane to a vacuole under the influence of lactate. Despite the overexpression of the CDR1 gene and the increased activity of Cdr1p, C. albicans is fourfold more sensitive to FLC in the presence of lactate than when glucose is the source of carbon. We propose synergistic effects of lactate and FLC in that they block Cdr1 activity by delocalization due to changes in the ergosterol content of the plasma membrane. Citation: Suchodolski, J.; Muraszko, J.; Bernat, P.; Krasowska, A. Lactate Keywords: Candida albicans; lactate; fluconazole; ergosterol; Cdr1 Like Fluconazole Reduces Ergosterol Content in the Plasma Membrane and Synergistically Kills Candida albicans.
    [Show full text]
  • United States Patent (10) Patent No.: US 8.450,378 B2 Snyder Et Al
    USOO8450378B2 (12) United States Patent (10) Patent No.: US 8.450,378 B2 Snyder et al. (45) Date of Patent: *May 28, 2013 (54) ANTIVIRAL METHOD 5,944.912 A 8/1999 Jenkins ........................... 134/40 5,951,993 A 9, 1999 Scholz. ....... ... 424/405 (75) Inventors: Marcia Snyder, Stow, OH (US); David 6,022,5515,965,610 A 10/19992/2000 JampaniModak et ..... al. ... 424/405514,494 R. Macinga, Stow, OH (US); James W. 6,025,314. A 2/2000 Nitsch ... ... 510,221 Arbogast, Bath, OH (US) 6,034,133. A 3/2000 Hendley . 514,573 6,080,417 A 6/2000 Kramer ......................... 424/405 (73) Assignee: GOJO Industries, Inc., Akron, OH 6,090,395 A 7/2000 ASmuS (US) 6,107,261 A 8/2000 Taylor ........................... 510,131 6,110,908 A 8/2000 Guthery . 514,188 (*) Notice: Subject to any disclaimer, the term of this 8:35, A 858 Flying . patent is extended or adjusted under 35 6,183,766 B1 2/2001 Sine et al. ... 424/405 U.S.C. 154(b) by 716 days. 6,204.230 B1 3/2001 Taylor ........ ... 510,131 6,294, 186 B1 9/2001 Beerse et al. ... 424/405 This patent is Subject to a terminal dis- 6,319,958 B1 1 1/2001 Johnson ..... 514,739 claimer. 6,326,430 B1 12/2001 Berte ..... 524,555 6,352,701 B1 3/2002 Scholz. ... ... 424/405 (21) Appl. No.: 12/189,139 6,423,329 B1 7/2002 Sine et al. .. ... 424/405 6,436,885 B2 8/2002 Biedermann . ... 510,131 6,468,508 B1 10/2002 Laughlin ..
    [Show full text]
  • Antifungal Effects of Lactobacillus Species Isolated from Local Dairy Products
    [Downloaded free from http://www.jpionline.org on Sunday, September 17, 2017, IP: 78.39.35.67] Original Research Article Antifungal effects of Lactobacillus species isolated from local dairy products Sahar Karami, Mohammad Roayaei, Elnaz Zahedi, Mahmoud Bahmani1, Leila Mahmoodnia2, Hosna Hamzavi, Mahmoud Rafieian-Kopaei3 Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahwaz, 1Department of Pharmacology, Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, 3Department of Pharmacology, Medical Plants Research Center, Basic Health Sciences Institute, 2Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran Abstract Objective: The Lactobacillus is a genus of lactic acid bacteria which are regularly rod‑shaped, nonspore, Gram‑positive, heterogeneous, and are found in a wide range of inhabitants such as dairy products, plants, and gastrointestinal tract. A variety of antimicrobial compounds and molecules such as bacteriocin are produced by these useful bacteria to inhibit the growth of pathogenic microbes in the food products. This paper aims to examine the isolation of Lactobacillus from local dairies as well as to determine their inhibition effect against a number of pathogens, such as two fungi: Penicillium notatum and Aspergillus fulvous. Materials and Methods: Twelve Lactobacillus isolates from several local dairies. After initial dilution (10−1–10−3) and culture on the setting, de Man, Rogosa and Sharpe‑agar, the isolates were recognized and separated by phenotypic characteristics and biochemical; then their antifungal effect was examined by two methods. Results: Having separated eight Lactobacillus isolates, about 70% of the isolates have shown the inhabiting areas of antifungus on the agar‑based setting, but two species Lactobacillus alimentarius and Lactobacillus delbrueckii have indicated a significant antifungal effect against P.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008
    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 William A. Rutala, Ph.D., M.P.H.1,2, David J. Weber, M.D., M.P.H.1,2, and the Healthcare Infection Control Practices Advisory Committee (HICPAC)3 1Hospital Epidemiology University of North Carolina Health Care System Chapel Hill, NC 27514 2Division of Infectious Diseases University of North Carolina School of Medicine Chapel Hill, NC 27599-7030 1 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 3HICPAC Members Robert A. Weinstein, MD (Chair) Cook County Hospital Chicago, IL Jane D. Siegel, MD (Co-Chair) University of Texas Southwestern Medical Center Dallas, TX Michele L. Pearson, MD (Executive Secretary) Centers for Disease Control and Prevention Atlanta, GA Raymond Y.W. Chinn, MD Sharp Memorial Hospital San Diego, CA Alfred DeMaria, Jr, MD Massachusetts Department of Public Health Jamaica Plain, MA James T. Lee, MD, PhD University of Minnesota Minneapolis, MN William A. Rutala, PhD, MPH University of North Carolina Health Care System Chapel Hill, NC William E. Scheckler, MD University of Wisconsin Madison, WI Beth H. Stover, RN Kosair Children’s Hospital Louisville, KY Marjorie A. Underwood, RN, BSN CIC Mt. Diablo Medical Center Concord, CA This guideline discusses use of products by healthcare personnel in healthcare settings such as hospitals, ambulatory care and home care; the recommendations are not intended for consumer use of the products discussed. 2
    [Show full text]
  • Calcium Chloride
    Iodine Livestock 1 2 Identification of Petitioned Substance 3 4 Chemical Names: 7553-56-2 (Iodine) 5 Iodine 11096-42-7 (Nonylphenoxypolyethoxyethanol– 6 iodine complex) 7 Other Name: 8 Iodophor Other Codes: 9 231-442-4 (EINECS, Iodine) 10 Trade Names: CAS Numbers: 11 FS-102 Sanitizer & Udderwash 12 Udder-San Sanitizer and Udderwash 13 14 Summary of Petitioned Use 15 The National Organic Program (NOP) final rule currently allows the use of iodine in organic livestock 16 production under 7 CFR §205.603(a)(14) as a disinfectant, sanitizer and medical treatment, as well as 7 CFR 17 §205.603(b)(3) for use as a topical treatment (i.e., teat cleanser for milk producing animals). In this report, 18 updated and targeted technical information is compiled to augment the 1994 Technical Advisory Panel 19 (TAP) Report on iodine in support of the National Organic Standard’s Board’s sunset review of iodine teat 20 dips in organic livestock production. 21 Characterization of Petitioned Substance 22 23 Composition of the Substance: 24 A variety of substances containing iodine are used for antisepsis and disinfection. The observed activity of 25 these commercial disinfectants is based on the antimicrobial properties of molecular iodine (I2), which 26 consists of two covalently bonded atoms of elemental iodine (I). For industrial uses, I2 is commonly mixed 27 with surface-active agents (surfactants) to enhance the water solubility of I2 and also to sequester the 28 available I2 for extended release in disinfectant products. Generally referred to as iodophors, these 29 “complexes” consist of up to 20% I2 by weight in loose combination with nonionic surfactants such as 30 nonylphenol polyethylene glycol ether (Lauterbach & Uber, 2011).
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Isolation and Characterization of Lactic Acid Bacteria (Lactobacillus Sp.) from Sauerkraut Resti Fevria 1* Indra Hartanto 1
    Advances in Biological Sciences Research, volume 10 International Conference on Biology, Sciences and Education (ICoBioSE 2019) Isolation and Characterization of Lactic Acid Bacteria (Lactobacillus sp.) From Sauerkraut Resti Fevria 1* Indra Hartanto 1 1 Biology Department Math and Natural Science FacultyPadang State University Padang, Indonesia *Corresponding author. [email protected] ABSTRACT Sauerkraut is fermented product based on cabbage with the addition of 2.5 percent salt. Sauerkraut can last a long time and has a pretty acidic taste, this is caused by lactic acid bacteria that form during fermentation. Fermentation is a part of biotechnology that uses microorganisms as the main actors in a process. One of the microbes that determines the success of fermentation is lactic acid bacteria. The purpose of this study is to isolate LAB from Sauerkraut, the type of LAB produced microscopically. Research methods, the ingredients used are cabbage fermentation (sauerkraut), MRSa , 0.9% NaCl , crystal violet paint from biological laboratories UNP. LAB isolation from Sauerkraut done in fermentation with Sauerkraut and then plant the sauerkraut into the MRSa medium with streak plate methods. The isolates obtained were identified microscopically using a microscope with gram staining method. From the research that has been done, the following result are Obtained: Sauerkraut direcly into MRSA medium and gram staining, there were 1 7 colonies of gram-positive bacteria with bacil cell form, and negative catalase test. We can identify these colonies as Lactobacillius sp. Keywords: Isolation, Sauerkraut, Lactic Acid Bacteria, Lactobacillus sp. ingredient will be inhibited if there is lactic acid bacteria in [2] 1. INTRODUCTION the material .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • PRAC Draft Agenda of Meeting 11-14 May 2020
    11 May 2020 EMA/PRAC/257460/2020 Human Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 11-14 May 2020 Chair: Sabine Straus – Vice-Chair: Martin Huber 11 May 2020, 10:30 – 19:30, via teleconference 12 May 2020, 08:30 – 19:30, via teleconference 13 May 2020, 08:30 – 19:30, via teleconference 14 May 2020, 08:30 – 16:00, via teleconference Organisational, regulatory and methodological matters (ORGAM) 28 May 2020, 09:00-12:00, via teleconference Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Antiseptics in the Era of Bacterial Resistance: a Focus on Povidone Iodine
    Therapeutic Perspective Antiseptics in the era of bacterial resistance: a focus on povidone iodine Jean-Marie Lachapelle*1, Olivier Castel2, Alejandro Fueyo Casado3, Bernard Leroy1, Giuseppe Micali4, Dominique Tennstedt1 & Julien Lambert5 Practice Points Increasing bacterial resistance to antibiotics makes the management of superficial skin infections a major medical challenge. Antiseptics have broader spectrums of antimicrobial activity and a reduced potential for selection of bacterial resistance, relative to antibiotics. Consequently, antiseptics are appropriate alternatives to antibiotics for the prevention and treatment of superficial skin infections. Of four widely used antiseptics (povidone iodine, polihexanide, chlorhexidine and octenidine), povidone iodine has a particularly broad spectrum of antimicrobial activity that includes Gram-positive and Gram-negative bacteria, bacterial spores, fungi, protozoa and viruses. Widespread and extended use of povidone iodine is not associated with the selection of resistant bacterial strains. In contrast, bacterial resistance to chlorhexidine, quaternary ammonium salts, silver and triclosan has been documented. Regarding duration of effect on healthy skin, chlorhexidine is active for 1–4 h, whereas solutions of povidone iodine are active for 12–14 h. Aqueous and hydroalcoholic formulations of povidone iodine have good skin tolerance. Povidone iodine scrub has better skin tolerance than soap formulations of chlorhexidine and quaternary ammonium compounds (e.g., benzalkonium chloride and
    [Show full text]